Coldrif Sales Suspended Across Tamil Nadu
Chennai – The Tamil Nadu government has banned the sale of Coldrif cough syrup after alarming reports linked the medicine to the deaths of 11 children in Madhya Pradesh and Rajasthan. The ban, effective from October 1, applies statewide, according to officials from the Food Safety and Drug Administration Department.
Authorities carried out inspections at the manufacturer’s facility in Sunguvarchathram, Kancheepuram district. During the inspection, multiple samples of the syrup were collected for laboratory analysis. Officials confirmed that the company supplies Coldrif to Madhya Pradesh, Rajasthan, and Puducherry.
Laboratory tests will check for diethylene glycol, a toxic chemical previously found in contaminated cough syrups linked to child fatalities. Officials said results are expected within days, and the Union government will also conduct parallel testing.
Union Advisory on Cough Syrups for Children
Following the child deaths, the Union Health Ministry issued an advisory to all states and union territories. The directive, sent by the Directorate General of Health Services, warned against prescribing cough and cold medicines to children below two years of age.
The advisory comes amid growing concerns over the safety of certain pediatric syrups after multiple tragedies in different states. Health experts have long cautioned that over-the-counter cough remedies may pose risks for infants and toddlers.
Tamil Nadu authorities confirmed that all existing stocks of Coldrif have been frozen. The manufacturer has also been ordered to halt production until the test results are released. “The department has been asked to prevent the sale of the syrup and freeze stocks from October 1,” an official said.
Madhya Pradesh and Rajasthan Deaths Raise Alarm
The deaths first drew attention in Madhya Pradesh’s Chhindwara district, where nine children reportedly died after consuming the syrup since September 7. Two more infant deaths were reported in Rajasthan under similar circumstances, heightening public concern.
Senior Congress leader Kamal Nath alleged that the tragedy in Madhya Pradesh may have been caused by a “brake oil solvent” mixed into the cough syrup. His remarks intensified political debate over the state’s regulatory oversight and accountability.
The reports have sparked nationwide concern, with both state and central authorities stepping up inspections of pharmaceutical production units. Public health activists argue that the incidents highlight systemic lapses in quality control, particularly in medicines supplied for pediatric use.
Safety Concerns Over Pediatric Syrups
This is not the first time India has faced controversy over cough syrups linked to child deaths. Several past incidents, including cases flagged by international agencies, revealed the presence of diethylene glycol in unsafe concentrations. The chemical is often used as an industrial solvent and can be fatal if ingested.
Health experts stress that the current incident underscores the urgent need for stronger regulatory checks. “Each tragedy weakens public trust in basic medicines,” a Chennai-based pediatrician told local media. He urged parents not to administer cough syrups to infants without medical advice.
Tamil Nadu’s decision to act swiftly is being seen as a preventive measure while investigations continue. Officials reiterated that production will remain suspended until laboratory tests confirm whether contamination is responsible for the reported deaths.
Way Forward: Nationwide Monitoring
The Union government’s intervention signals that this may lead to stricter nationwide monitoring of cough syrup manufacturing. States have been instructed to strengthen vigilance and ensure compliance with safety standards.
If the lab reports confirm contamination, Coldrif could face a permanent ban, along with possible legal action against the manufacturer. In the meantime, health authorities are urging parents to exercise caution and consult doctors before giving any cough or cold medicines to children.